Competitive Landscape in Obesity Treatments
Eli Lilly’s recently introduced weight-loss medication, Foundayo, has experienced a modest performance in its second week of availability, according to analysts. This comes as the competition with Danish pharmaceutical giant Novo Nordisk intensifies in the burgeoning oral obesity drug market.
In the week ending April 17, Foundayo was prescribed 3,707 times in the U.S., a notable increase from its initial week where it garnered 1,390 prescriptions, as reported by IQVIA data. In contrast, Novo’s Wegovy, which debuted in January, achieved a much higher prescription volume: 18,410 in its second week, compared to 3,071 prescriptions in its first four days.
Analysts’ Perspectives on Prescription Trends
Market analysts had anticipated that Foundayo would accumulate approximately 8,000 prescriptions in its second week. Deutsche Bank analyst James Shin noted that achieving such a figure would suggest that Foundayo was maintaining a competitive trajectory against Wegovy. RBC Capital Markets analyst Trung Huynh expressed that while early comparisons are often seen as less critical, the lower-than-expected uptake of Foundayo this week may not be received positively.
As a result of these developments, Lilly’s stock experienced a decline of nearly 4%, while shares of Novo Nordisk saw an increase of about 6%. Truist analyst Srikripa Devarakonda pointed out that Foundayo’s prescription numbers represented only 20% of what Wegovy achieved during its initial full week, deeming this uptake as “modest.”
Market Share Battle
Investors are closely monitoring Foundayo’s rollout, viewing it as a crucial indicator of Lilly’s ability to capture market share from Novo Nordisk, which currently benefits from being a first mover in the oral weight-loss medication sector. J.P. Morgan analyst Chris Schott commented that Foundayo’s slower ramp-up compared to Wegovy was not unexpected, attributing this to Wegovy’s advantages in terms of brand recognition and time-to-market.
Foundayo received approval from the U.S. Food and Drug Administration on April 1, with prescriptions starting immediately through LillyDirect. The drug became widely available in retail pharmacies and telehealth services beginning April 9.
Interpretation of Early Data
Lilly has previously cautioned that the early weekly prescription figures may not provide a comprehensive picture of Foundayo’s market performance. The company indicated that these numbers should be interpreted over time rather than as definitive counts, suggesting a cautious approach to evaluating the medication’s uptake.
Conclusion
As the competition heats up between Lilly and Novo Nordisk in the oral obesity treatment market, Foundayo’s early performance raises questions about its future in a landscape dominated by Wegovy. Analysts and investors alike will be watching closely to see if Lilly can leverage its market presence and brand strategy to enhance Foundayo’s prescription numbers in the upcoming weeks.
- Foundayo’s second-week prescriptions show modest growth compared to its launch.
- Novo’s Wegovy continues to dominate the market with significantly higher prescription rates.
- Analysts express concerns about Foundayo’s slower uptake in a competitive landscape.
- Investors are keenly observing the rollout for signs of market share gains.
- Early prescription data should be interpreted cautiously, as broader trends may take time to emerge.
Read more → www.aol.com